CDH3 and breast cancer: Among non-basal cases, defined by absence of the ER− HER2− CK5+ profile or ER− HER2− P-cadherin + profile, Nestin was significantly associated with poorer breast cancer specific survival (log-rank test, p = 0.003 and p = 0.004, respectively).